Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 5/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 11/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5340478 | 0.94 | EPHX2 (0.37) | EPHX2EPHX1KDM4EALDH1A1GAA | |
| SCHEMBL4882082 | 0.90 | EPHX1 (0.39) | EPHX2EPHX1KDM4EALDH1A1GAA | |
| SCHEMBL4792739 | 0.89 | EPHX1 (0.38) | EPHX2EPHX1KDM4EALDH1A1GAA | |
| SCHEMBL5335479 | 0.88 | EPHX1 (0.37) | EPHX2EPHX1KDM4EALDH1A1GAA | |
| SCHEMBL5341182 | 0.88 | EPHX1 (0.37) | EPHX2EPHX1KDM4EALDH1A1GAA | |
| SCHEMBL5337857 | 0.88 | EPHX1 (0.43) | EPHX2EPHX1DOT1L | |
| SCHEMBL4792032 | 0.86 | EPHX1 (0.36) | EPHX2EPHX1KDM4EALDH1A1GAA | |
| SCHEMBL5349677 | 0.84 | EPHX1 (0.38) | EPHX2EPHX1GAATDP1DOT1L | |
| SCHEMBL5336947 | 0.83 | EPHX1 (0.40) | EPHX2EPHX1KDM4EALDH1A1GAA | |
| SCHEMBL4791828 | 0.81 | TLR7 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7220758-B2 | Ether substituted imidazopyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2007-05-22 | — | — | US | disclosed |
| US-20060252792-A1 | ETHER SUBSTITUTED IMIDAZOPYRIDINES | 3M INNOVATIVE PROPERTIES COMPANY | 2006-11-09 | — | — | US | disclosed |
| US-7125890-B2 | Ether substituted imidazopyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2006-10-24 | — | — | US | disclosed |
| US-20050032830-A1 | Immunology for viral diseases and biosynthesis of cytokines of anticancer drugs for tumors | 3M INNOVATIVE PROPERTIES COMPANY | 2005-02-10 | — | — | US | disclosed |
| US-6797718-B2 | Ether substituted imidazopyridines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-09-28 | — | — | US | disclosed |
| US-20040010007-A1 | Ether substituted imidazopyridines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252792-A1 | ETHER SUBSTITUTED IMIDAZOPYRIDINES | IL2, IL4, MYD88 | EPHX2 762/4885EPHX1 386/4885KDM4E 869/4885 |
| US-20050032830-A1 | Immunology for viral diseases and biosynthesis of cytokines of anticancer drugs for tumors | IL2, IFNG, TSLP | EPHX2 704/4885EPHX1 259/4885KDM4E 994/4885 |
| US-20040010007-A1 | Ether substituted imidazopyridines | IL2, IL4, MYD88 | EPHX2 762/4885EPHX1 386/4885KDM4E 869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.